BioCorRx (BICX) Gains from Investment Securities (2015 - 2025)

BioCorRx (BICX) has 12 years of Gains from Investment Securities data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Gains from Investment Securities changed N/A year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.7 million, up 21.61% from the prior year.
• Gains from Investment Securities advanced to $1.7 million in Q1 2026 per BICX's latest filing, from $1.6 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $1.7 million in Q1 2026, with the low at $843004.0 in Q2 2022.
• Average Gains from Investment Securities over 5 years is $1.2 million, with a median of $913255.5 recorded in 2023.
• The widest YoY moves for Gains from Investment Securities: up 4.82% in 2022, down 2.98% in 2022.
• BioCorRx's Gains from Investment Securities stood at $858101.0 in 2022, then increased by 3.89% to $891443.0 in 2023, then advanced by 4.89% to $935068.0 in 2024, then jumped by 72.18% to $1.6 million in 2025, then grew by 3.67% to $1.7 million in 2026.
• Business Quant data shows BICX's Gains from Investment Securities at $1.7 million in Q1 2026, $1.6 million in Q3 2025, and $1.5 million in Q2 2025.